LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today reported financial results for the second quarter ended June 30, 2015 and provided a pipeline update.
“The ganetespib development program is approaching its first key milestone, with the Phase 3 GALAXY-2 trial in non-small cell lung cancer nearing its first interim analysis, which is anticipated by year end, followed by the second interim and final analyses expected in 2016,” said Chen Schor, President and Chief Executive Officer of Synta.
Help employers find you! Check out all the jobs and post your resume.
“The ganetespib development program is approaching its first key milestone, with the Phase 3 GALAXY-2 trial in non-small cell lung cancer nearing its first interim analysis, which is anticipated by year end, followed by the second interim and final analyses expected in 2016,” said Chen Schor, President and Chief Executive Officer of Synta.
Help employers find you! Check out all the jobs and post your resume.
